Find a Doctor or Practice Location

Are you a referring physician?
I am searching for a
Reset Form
Ravi K. Amaravadi, MD

Ravi K. Amaravadi, MD Physician

Associate Professor of Medicine at the Hospital of the University of Pennsylvania

Dr. Amaravadi is employed by Penn Medicine.

Patient Satisfaction Ratings

Patient Rating Breakdown

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

The comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Overall Ratings

Patient Comments

Clinical Specialties


  • Medical Oncology

Programs & Centers:

Board Certification:

  • Medical Oncology, 2006

Clinical Expertise:

  • Melanoma
  • Skin Cancer

Description of Clinical Expertise

Phase I and Phase II Clinical Trials

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • CVS Health
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: Johns Hopkins University School of Medicine
Residency: Brigham and Women's Hospital
Fellowship: Hospital of the University of Pennsylvania


American Association for Cancer Research , National American Association for the Advancement of Science, National American Society of Clinical Oncology, National Austrian Science Fund (FWF),, International Beyond Batten Disease Foundation , International Health Frontiers Science Program, France, International Health Research Ireland , International Icelandic Research Fund , International Immunaccel Biosciences, National Melanoma Research Foundation , National Melanoma Research Foundation Breakthrough Consortium , National NCI-J special emphasis panel study section for K awards, National Newcastle University, UK , International NIH Loan repayment program , National OPUS, National Science Center, OPUS , International Presage Biosciences , National Sprint Biosciences , International Welcome Trust DBT alliance Post doctoral fellowships, India , International Wistar Institute, Cancer Center, Tumor Microenvironment and Metastases Program , Local

Hospital Affiliation

Dr. Amaravadi is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.


Description of Research Expertise:

Autophagy, Mechanisms of Cell Death, Developmental Therapeutics

Selected Publications:

Yam Clinton, Xu Xiaowei, Davies Michael A, Gimotty Phyllis A, Morrissette Jennifer J D, Tetzlaff Michael T, Wani Khalida M, Liu Shujing, Deng Wanleng, Buckley Meghan, Zhao Jianhua, Amaravadi Ravi K, Haas Naomi B, Kudchadkar Ragini R, Pavlick Anna C, Sosman Jeffrey A, Tawbi Hussein, Walker Luke, Schuchter Lynn M, Karakousis Giorgos C, Gangadhar Tara C: A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 24 (1): 22-32,2018.

Sinnamon Andrew J, Neuwirth Madalyn G, Gimotty Phyllis A, Gangadhar Tara C, Amaravadi Ravi K, Schuchter Lynn M, Karakousis Giorgos C: Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma. JAMA oncology 4 (1): 126-128,2018.

Nti Akosua A, Serrano Leona W, Sandhu Harpal S, Uyhazi Katherine E, Edelstein Ilaina D, Zhou Elaine J, Bowman Scott, Song Delu, Gangadhar Tara C, Schuchter Lynn M, Mitnick Sheryl, Huang Alexander, Nichols Charles W, Amaravadi Ravi K, Kim Benjamin J, Aleman Tomas S: FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial. Retina (Philadelphia, Pa.) : 2018.

Garman Bradley, Anastopoulos Ioannis N, Krepler Clemens, Brafford Patricia, Sproesser Katrin, Jiang Yuchao, Wubbenhorst Bradley, Amaravadi Ravi, Bennett Joseph, Beqiri Marilda, Elder David, Flaherty Keith T, Frederick Dennie T, Gangadhar Tara C, Guarino Michael, Hoon David, Karakousis Giorgos, Liu Qin, Mitra Nandita, Petrelli Nicholas J, Schuchter Lynn, Shannan Batool, Shields Carol L, Wargo Jennifer, Wenz Brandon, Wilson Melissa A, Xiao Min, Xu Wei, Xu Xaiowei, Yin Xiangfan, Zhang Nancy R, Herlyn Meenhard: Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. Cell reports 21 (7): 1936-1952,2017.

Lu Hezhe, Liu Shujing, Zhang Gao, Bin Wu, Zhu Yueyao, Frederick Dennie T, Hu Yi, Zhong Wenqun, Randell Sergio, Sadek Norah, Zhang Wei, Chen Gang, Cheng Chaoran, Zeng Jingwen, Wu Lawrence W, Zhang Jie, Liu Xiaoming, Xu Wei, Krepler Clemens, Sproesser Katrin, Xiao Min, Miao Benchun, Liu Jianglan, Song Claire D, Liu Jephrey Y, Karakousis Giorgos C, Schuchter Lynn M, Lu Yiling, Mills Gordon, Cong Yusheng, Chernoff Jonathan, Guo Jun, Boland Genevieve M, Sullivan Ryan J, Wei Zhi, Field Jeffrey, Amaravadi Ravi K: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature 550 (7674): 133-136,2017.

Ndoye Abibatou, Budina-Kolomets Anna, Kugel Curtis H, Webster Marie R, Kaur Amanpreet, Behera Reeti, Rebecca Vito W, Li Ling, Brafford Patricia A, Liu Qin, Vashisht Gopal Y N, Davies Michael A, Mills Gordon B, Xu Xiaowei, Wu Hong, Herlyn Meenhard, Nicastri Michael C, Winkler Jeffrey D, Soengas Maria S, Amaravadi Ravi K, Murphy Maureen E, Weeraratna Ashani T: ATG5 mediates a positive feedback loop between Wnt signaling and autophagy in melanoma. Cancer research 77 (21): 5873-5885,2017.

Zhang Ying, Kurupati Raj, Liu Ling, Zhou Xiang Yang, Zhang Gao, Hudaihed Abeer, Filisio Flavia, Giles-Davis Wynetta, Xu Xiaowei, Karakousis Giorgos C, Schuchter Lynn M, Xu Wei, Amaravadi Ravi, Xiao Min, Sadek Norah, Krepler Clemens, Herlyn Meenhard, Freeman Gordon J, Rabinowitz Joshua D, Ertl Hildegund C J: Enhancing CD8(+) T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. Cancer Cell 32 (3): 377-391.e9,2017.

Rebecca Vito W, Nicastri Michael C, McLaughlin Noel, Fennelly Colin, McAfee Quentin, Ronghe Amruta, Nofal Michel, Lim Chun-Yan, Witze Eric, Chude Cynthia I, Zhang Gao, Alicea Gretchen M, Piao Shengfu, Murugan Sengottuvelan, Ojha Rani, Levi Samuel M, Wei Zhi, Barber-Rotenberg Julie S, Murphy Maureen E, Mills Gordon B, Lu Yiling, Rabinowitz Joshua, Marmorstein Ronen, Liu Qin, Liu Shujing, Xu Xiaowei, Herlyn Meenhard, Zoncu Roberto, Brady Donita C, Speicher David W, Winkler Jeffrey D, Amaravadi Ravi K: A unified approach to targeting the lysosome's degradative and growth signaling roles. Cancer discovery 7 (11): 1266-1283,2017.

Gangadhar Tara C, Savitch Samantha L, Yee Stephanie S, Xu Wei, Huang Alexander C, Harmon Shannon, Lieberman David B, Soucier Devon, Fan Ryan, Black Taylor A, Morrissette Jennifer J D, Salathia Neeraj, Waters Jill, Zhang Shile, Toung Jonathan, van Hummelen Paul, Fan Jian-Bing, Xu Xiaowei, Amaravadi Ravi K, Schuchter Lynn M, Karakousis Giorgos C, Hwang Wei-Ting, Carpenter Erica L: Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma. Pigment cell & melanoma research 31 (1): 73-81,2017.

Izar Benjamin, Sharfman William, Hodi F Stephen, Lawrence Donald, Flaherty Keith T, Amaravadi Ravi, Kim Kevin B, Puzanov Igor, Sosman Jeffrey, Dummer Reinhard, Goldinger Simone M, Lam Lyhping, Kakar Shefali, Tang Zhongwen, Krieter Oliver, McDermott David F, Atkins Michael B: A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. Cancer medicine 6 (8): 1904-1914,2017.

Academic Contact Info

Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-201
3400 Civic Center Blvd

Philadelphia, PA 19104
Phone: (215) 662-7402
Patient appointments: 800-789-7366 (PENN)

Related Links